4//SEC Filing
Ryan Charles S. 4
Accession 0001104659-20-132153
CIK 0001513856other
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 9:41 PM ET
Size
14.3 KB
Accession
0001104659-20-132153
Insider Transaction Report
Form 4
Neurotrope, Inc.NTRP
Ryan Charles S.
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2020-12-01−150,000→ 0 totalExercise: $3.93→ Common Stock (150,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-12-01−40,000→ 0 totalExercise: $0.97→ Common Stock (40,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-12-01−157,918→ 0 totalExercise: $7.55→ Common Stock (157,918 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-12-01−79,097→ 0 totalExercise: $4.37→ Common Stock (79,097 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-12-01−130,680→ 0 totalExercise: $0.78→ Common Stock (130,680 underlying)
Footnotes (1)
- [F1]Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Documents
Issuer
Neurotrope, Inc.
CIK 0001513856
Entity typeother
Related Parties
1- filerCIK 0001624830
Filing Metadata
- Form type
- 4
- Filed
- Dec 2, 7:00 PM ET
- Accepted
- Dec 3, 9:41 PM ET
- Size
- 14.3 KB